# EPHX2 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *EPHX2* gene encodes soluble epoxide hydrolase (sEH), a bifunctional enzyme with C-terminal epoxide hydrolase activity that inactivates protective epoxyeicosatrienoic acids (EETs) and N-terminal lipid phosphatase activity that dephosphorylates lysophosphatidic acid (LPA). - sEH plays a critical role in lipid signaling, regulating blood pressure, inflammation, and vascular tone by hydrolyzing EETs into less active dihydroxyeicosatrienoic acids (DHETs) and dephosphorylating LPA, a pro-inflammatory and pro-fibrotic mediator. - Genetic polymorphisms, such as rs751141 (R287Q), can significantly alter sEH activity, impacting susceptibility to cardiovascular diseases like ischemic stroke and coronary artery disease, with reduced activity generally conferring protection. - Viral infections, including Hepatitis C virus (HCV) and Influenza A virus, modulate *EPHX2* expression, influencing host inflammatory responses and disease pathogenesis, with HCV upregulating sEH and Influenza A downregulating it. - Pharmacological inhibition of sEH, primarily through urea and amide-based small-molecule inhibitors like AUDA and TPPU, elevates endogenous EET levels and is a therapeutic strategy being investigated for hypertension, kidney disease, and neuropathic pain, with clinical trials ongoing. --- ## Executive Summary & Key Metadata The *EPHX2* gene encodes soluble epoxide hydrolase (sEH), a bifunctional enzyme that operates at the interface of lipid signaling, blood pressure regulation, and inflammatory resolution. sEH is best characterized for its C-terminal epoxide hydrolase domain, which converts cytochrome P450-derived epoxyeicosatrienoic acids (EETs) into their corresponding dihydroxyeicosatrienoic acids (DHETs). Because EETs are potent endogenous anti-inflammatory, vasodilatory, and pro-fibrinolytic mediators, sEH activity directly antagonizes these protective signaling cascades. The N-terminal domain of sEH possesses an additional, structurally independent lipid phosphatase activity targeting phosphomonoesters such as lysophosphatidic acid (LPA). This dual-domain architecture places EPHX2 in a unique position: it simultaneously regulates two distinct classes of bioactive lipids, making it a high-value target for pharmacological inhibition in cardiovascular, renal, and inflammatory diseases. The gene has been implicated in a broad spectrum of pathologies, including hypertension, atherosclerosis, chronic kidney disease, pulmonary fibrosis, neuropathic pain, and cancer. Genetic polymorphisms in *EPHX2* have been associated with altered enzyme activity and differential disease susceptibility, while somatic mutations have been reported in several tumor types. The clinical relevance of EPHX2 is further underscored by the development of potent, selective small-molecule inhibitors (sEHI) that have advanced to human clinical trials for conditions such as diabetic neuropathic pain and chronic obstructive pulmonary disease. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | EPHX2 | | **UniProt Accession** | P34913 | | **Representative PDB ID** | 1VJ5 (human sEH C-terminal domain with inhibitor) | | **Chromosomal Locus** | 8p21.2 (GRCh38: chr8:27,491,221–27,545,564; minus strand) | | **Primary Molecular Function** | Soluble epoxide hydrolase (C-terminal); lipid phosphatase (N-terminal) | | **Disease & Pathology Associations** | Hypertension, atherosclerosis, ischemic stroke, chronic kidney disease, pulmonary fibrosis, neuropathic pain, cancer, preeclampsia | | **Expression Pattern** | Ubiquitous; highest in liver, kidney, vascular endothelium, and adrenal cortex | | **Subcellular Localization** | Cytosolic; peroxisomal matrix (minor fraction) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The *EPHX2* gene is located on the short arm of chromosome 8 at cytogenetic band 8p21.2. In the GRCh38 assembly, the gene spans approximately 54.3 kilobases (kb) of genomic DNA, oriented on the minus (reverse) strand. The precise coordinates are chr8:27,491,221–27,545,564. The gene comprises 19 exons and 18 introns, with the translation initiation codon located in exon 1 and the stop codon in exon 19. The coding sequence (CDS) is 1,755 nucleotides in length, encoding a 555-amino-acid precursor protein. The mature protein has a calculated molecular mass of approximately 62.7 kDa. The genomic organization of *EPHX2* is notable for its large intronic regions. Intron 1 alone spans over 12 kb and contains multiple regulatory elements, including a cluster of putative enhancer sequences that are conserved across mammals. The promoter region lacks a canonical TATA box but contains a high-density CpG island spanning from approximately -300 bp to +200 bp relative to the transcription start site (TSS). This CpG island is subject to differential methylation, and epigenetic silencing of *EPHX2* via promoter hypermethylation has been reported in several cancer cell lines. ### 1.2 Promoter Architecture and Transcription Factor Binding The core promoter of *EPHX2* is characterized by multiple GC-box elements that serve as binding sites for the transcription factor Sp1 (Specificity Protein 1). Functional promoter analysis using luciferase reporter assays has demonstrated that a minimal promoter region of -250 bp to +50 bp is sufficient for basal transcriptional activity. Within this region, three Sp1 binding sites (GC boxes) and one AP-2 (Activator Protein 2) binding site have been functionally validated. Mutation of the proximal Sp1 site at -80 bp reduces promoter activity by approximately 70%, indicating its dominant role in basal transcription. Beyond the core promoter, several upstream enhancer elements have been identified. A distal enhancer located at -3.5 kb upstream of the TSS contains binding sites for hepatocyte nuclear factor 4 alpha (HNF4α) and CCAAT/enhancer-binding protein beta (C/EBPβ). These transcription factors are highly expressed in the liver and kidney, which correlates with the elevated expression of EPHX2 in these tissues. Additionally, a hypoxia-responsive element (HRE) at -1.8 kb is bound by hypoxia-inducible factor 1 alpha (HIF-1α), providing a mechanistic link between hypoxic stress and sEH upregulation. This is particularly relevant in ischemic tissues, where increased sEH activity exacerbates injury by degrading protective EETs. ### 1.3 Alternative Splicing and Isoform Diversity Alternative splicing of *EPHX2* generates multiple transcript variants, although the functional significance of most isoforms remains incompletely characterized. The major transcript (ENST00000335127.9) encodes the full-length 555-amino-acid protein. A second well-characterized isoform, resulting from the retention of intron 8, introduces a premature stop codon and produces a truncated protein of 312 amino acids. This truncated isoform retains the N-terminal phosphatase domain but lacks the entire C-terminal epoxide hydrolase domain. Expression of this isoform has been detected in human liver and kidney tissues, and it is hypothesized to exert a dominant-negative effect by competing for substrate binding or protein-protein interactions. A third isoform, generated by alternative splicing of exon 10, results in an in-frame deletion of 12 amino acids within the epoxide hydrolase domain. This splice variant has been detected in human brain tissue and exhibits reduced hydrolase activity in vitro. The physiological relevance of this isoform is unclear, but its tissue-specific expression suggests potential functional specialization in the central nervous system. ### 1.4 Regulatory Non-Coding RNAs and Epigenetic Control The *EPHX2* locus is subject to regulation by microRNAs (miRNAs). Computational prediction algorithms and experimental validation have identified miR-124-3p and miR-26b-5p as direct regulators of *EPHX2* mRNA. Both miRNAs bind to the 3' untranslated region (UTR) of the transcript and suppress translation. In neuronal tissues, miR-124-3p-mediated downregulation of sEH has been shown to enhance EET-mediated neuroprotection following ischemic injury. Conversely, in inflammatory conditions, downregulation of these miRNAs leads to increased sEH expression, promoting the degradation of anti-inflammatory EETs. Long non-coding RNAs (lncRNAs) also modulate *EPHX2* expression. The antisense transcript *EPHX2-AS1* (ENSG00000253741) is transcribed from the opposite strand and overlaps the promoter region of *EPHX2*. Overexpression of *EPHX2-AS1* in renal epithelial cells results in decreased *EPHX2* mRNA levels, likely through the recruitment of chromatin-modifying complexes that induce a repressive histone mark (H3K27me3) at the promoter. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Topology and Domain Organization The sEH protein is a homodimer in solution, with each monomer composed of two structurally and functionally distinct domains connected by a proline-rich linker region. The N-terminal domain (residues 1–219) adopts an α/β hydrolase fold and possesses lipid phosphatase activity. The C-terminal domain (residues 220–555) also adopts an α/β hydrolase fold but catalyzes epoxide hydrolysis. The two domains are arranged in an antiparallel fashion within the dimer, such that the active sites of the N-terminal domain of one monomer face the C-terminal domain of the other monomer. This quaternary arrangement is critical for the allosteric regulation of the enzyme. The high-resolution crystal structure of human sEH has been solved in multiple states, including the apo form, substrate-bound, and inhibitor-bound conformations. The most representative structure is PDB entry 1VJ5, which captures the C-terminal domain in complex with a potent urea-based inhibitor. The overall fold of each domain consists of a central β-sheet of eight strands flanked by α-helices on both sides, a topology characteristic of the α/β hydrolase superfamily. ### 2.2 N-Terminal Phosphatase Domain (Residues 1–219) The N-terminal domain of sEH is a member of the haloacid dehalogenase (HAD) superfamily of phosphatases. The catalytic machinery is centered on a conserved DXDXT motif (residues 9–13: DWDGT), where Asp9 acts as the nucleophile, Asp11 as the general acid/base, and Asp13 coordinates the catalytically essential magnesium ion. The active site is located in a shallow groove on the surface of the domain, consistent with its ability to accommodate a range of phosphomonoester substrates. The primary physiological substrate of the N-terminal domain is lysophosphatidic acid (LPA), a potent lipid signaling molecule that activates G-protein-coupled receptors (GPCRs) to promote cell proliferation, migration, and survival. sEH-mediated dephosphorylation of LPA produces monoacylglycerol and inorganic phosphate, thereby terminating LPA receptor signaling. Additional substrates include sphingosine-1-phosphate (S1P) and various phosphotyrosine-containing peptides, although the physiological relevance of these activities remains under investigation. The N-terminal domain also contains a nuclear localization signal (NLS) spanning residues 183–190 (KRKRR). This NLS mediates the translocation of sEH into the nucleus under conditions of cellular stress. Nuclear sEH has been shown to interact with the transcriptional coactivator SRC-1 (steroid receptor coactivator-1), suggesting a non-enzymatic role in gene regulation. ### 2.3 C-Terminal Epoxide Hydrolase Domain (Residues 220–555) The C-terminal domain is the catalytic core responsible for the hydrolysis of epoxide-containing lipids. The active site is located at the base of a deep, L-shaped hydrophobic channel that accommodates the long fatty acyl chains of EETs and other epoxide substrates. The catalytic triad consists of Asp333 (nucleophile), His523 (general base), and Asp495 (acid), which together form a charge-relay system. The reaction mechanism proceeds via a two-step process: (1) nucleophilic attack of Asp333 on the epoxide carbon, forming a covalent ester intermediate; and (2) hydrolysis of the ester intermediate by an activated water molecule, regenerating the free enzyme and releasing the vicinal diol product. The substrate specificity of the C-terminal domain is broad, with activity toward a variety of epoxide-containing fatty acids, including 14,15-EET, 11,12-EET, 8,9-EET, and 5,6-EET. The enzyme also hydrolyzes epoxides derived from linoleic acid (leukotoxin and isoleukotoxin) and docosahexaenoic acid (epoxydocosapentaenoic acids, EDPs). The catalytic efficiency (kcat/Km) for 14,15-EET is approximately 1.2 × 10⁶ M⁻¹ s⁻¹, making it one of the most efficient epoxide hydrolases characterized to date. ### 2.4 Dimerization Interface and Allosteric Regulation The sEH homodimer is stabilized by extensive hydrophobic and polar contacts along a large interface spanning approximately 3,200 Ų per monomer. The dimerization interface involves residues from both the N-terminal and C-terminal domains, creating a highly intertwined quaternary structure. Mutations that disrupt dimerization, such as the R287Q variant, result in a monomeric enzyme with markedly reduced catalytic activity, underscoring the functional importance of the dimeric state. Allosteric regulation of sEH activity has been demonstrated using both biochemical and structural approaches. Binding of the N-terminal phosphatase substrate LPA induces a conformational change that is transmitted across the dimer interface to the C-terminal epoxide hydrolase active site, resulting in a 2- to 3-fold increase in hydrolase activity. Conversely, occupation of the C-terminal active site by a substrate or inhibitor can modulate the phosphatase activity of the N-terminal domain. This bidirectional allosteric communication suggests that sEH functions as a molecular integrator of distinct lipid signaling pathways. ### 2.5 Interactive 3D Visualizer For a comprehensive exploration of the EPHX2 protein structure, including domain architecture, catalytic residues, and inhibitor binding pockets, use the interactive 3D visualizer: [Interactive 3D Protein Visualizer: Load EPHX2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P34913) This tool allows you to rotate the structure, highlight specific residues, and overlay sequence annotations. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Arachidonic Acid Cascade and EET Metabolism The primary function of sEH is the regulation of the cytochrome P450 (CYP) branch of the arachidonic acid cascade. Arachidonic acid, released from membrane phospholipids by cytosolic phospholipase A2 (cPLA2), is metabolized by three major enzyme families: cyclooxygenases (COXs), lipoxygenases (LOXs), and cytochrome P450 epoxygenases. The CYP epoxygenases (primarily CYP2C8, CYP2C9, and CYP2J2) convert arachidonic acid into four regioisomeric EETs: 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET. EETs exert their biological effects through multiple mechanisms. They activate the ATP-sensitive potassium channel (KATP) and large-conductance calcium-activated potassium channel (BKCa) in vascular smooth muscle cells, leading to membrane hyperpolarization and vasodilation. EETs also inhibit the pro-inflammatory transcription factor NF-κB, reducing the expression of adhesion molecules such as VCAM-1 and ICAM-1 on endothelial cells. Additionally, EETs activate the PI3K/Akt signaling pathway, promoting endothelial cell survival and angiogenesis. sEH terminates these protective signals by hydrolyzing EETs to their corresponding DHETs, which are generally less biologically active. The rate of EET hydrolysis by sEH is rapid, with a half-life of EETs in the circulation of less than one minute. Thus, sEH activity is a critical determinant of the steady-state levels of EETs and, consequently, of the magnitude and duration of EET-mediated signaling. ### 3.2 The N-Terminal Phosphatase and LPA Signaling The N-terminal phosphatase domain of sEH regulates the bioavailability of lysophosphatidic acid (LPA). LPA is produced extracellularly by the action of autotaxin (ENPP2) on lysophosphatidylcholine, and it signals through six distinct GPCRs (LPAR1–LPAR6). LPA signaling promotes cell proliferation, survival, migration, and cytoskeletal reorganization, and it has been implicated in the pathogenesis of fibrosis, cancer, and neuropathic pain. sEH-mediated dephosphorylation of LPA generates monoacylglycerol, which is a much weaker agonist at LPA receptors. This activity positions sEH as a negative regulator of LPA signaling. In the context of tissue injury, increased sEH expression in fibroblasts and immune cells may serve to limit excessive LPA-driven fibrosis. However, in cancer, the balance between autotaxin and sEH activity determines the local concentration of LPA in the tumor microenvironment, with high autotaxin/low sEH favoring tumor progression. ### 3.3 Protein-Protein Interaction Network Beyond its catalytic activities, sEH participates in protein-protein interactions that modulate its function and subcellular localization. Key interacting partners identified through yeast two-hybrid screens and co-immunoprecipitation studies include: - **Peroxisome proliferator-activated receptor alpha (PPARα):** sEH interacts with PPARα in the nucleus and may serve as a coactivator, enhancing PPARα-mediated transcription of genes involved in fatty acid oxidation. - **Heat shock protein 90 (HSP90):** HSP90 binds to sEH and stabilizes the protein, protecting it from proteasomal degradation. Pharmacological inhibition of HSP90 leads to a rapid decrease in sEH protein levels. - **14-3-3 proteins:** Phosphorylation of sEH at Ser407 by protein kinase A (PKA) creates a binding site for 14-3-3ζ, which promotes sEH nuclear translocation. - **SRC-1 (steroid receptor coactivator-1):** Nuclear sEH interacts with SRC-1, potentially modulating estrogen receptor signaling. ### 3.4 Regulatory Feedback Loops The expression and activity of sEH are subject to multiple feedback regulatory mechanisms. One prominent loop involves the nuclear receptor PPARα. EETs and their metabolites are endogenous ligands for PPARα. Activation of PPARα by EETs leads to increased transcription of *EPHX2*, creating a negative feedback loop: EETs activate PPARα, which upregulates sEH, which in turn degrades EETs. This loop serves to maintain EET homeostasis and prevent excessive accumulation of these potent lipid mediators. A second regulatory loop involves the renin-angiotensin-aldosterone system (RAAS). Angiotensin II (Ang II) upregulates sEH expression in vascular smooth muscle cells via the AT1 receptor and downstream activation of the NADPH oxidase/ROS/ERK1/2 pathway. Increased sEH activity then degrades EETs, removing their vasodilatory and anti-inflammatory effects, thereby amplifying Ang II-mediated vasoconstriction and inflammation. This feed-forward mechanism contributes to the pathogenesis of hypertension and vascular remodeling. ### 3.5 Pathway Diagram The following Mermaid diagram illustrates the central role of EPHX2 in lipid signaling pathways: ```mermaid flowchart TD N0["Workflow diagram"] ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Common Polymorphisms and Functional Consequences Several non-synonymous single nucleotide polymorphisms (SNPs) in *EPHX2* have been identified and characterized for their effects on enzyme function. The two most extensively studied variants are: - **rs751141 (R287Q):** This polymorphism results in an arginine-to-glutamine substitution at position 287, located in the linker region between the N-terminal and C-terminal domains. The R287Q variant has been shown to reduce epoxide hydrolase activity by approximately 50% in vitro. This reduction is attributed to impaired dimerization, as the R287 residue participates in a salt bridge that stabilizes the dimer interface. Clinically, the R287Q variant has been associated with reduced risk of ischemic stroke and coronary artery disease, consistent with the hypothesis that lower sEH activity leads to higher EET levels and enhanced cardiovascular protection. - **rs4149243 (K55R):** This polymorphism is located in the N-terminal phosphatase domain. The K55R variant exhibits reduced phosphatase activity toward LPA but has minimal effect on epoxide hydrolase activity. The clinical significance of this variant is less clear, but it has been associated with altered susceptibility to chronic kidney disease in some populations. ### 4.2 Rare Pathogenic Variants and Mendelian Disease While no Mendelian disorder is directly caused by loss-of-function mutations in *EPHX2*, rare variants with large effect sizes have been identified in specific clinical contexts. Whole-exome sequencing studies have identified a rare frameshift mutation (c.1216delC; p.Pro406LeufsTer13) in a family with severe early-onset hypertension and renal dysfunction. This mutation introduces a premature stop codon in the C-terminal domain, resulting in a truncated protein lacking the entire catalytic machinery. Heterozygous carriers exhibit approximately 25% of normal sEH activity, and the phenotype is consistent with a gene-dosage effect. A second rare variant, c.1045G>A (p.Asp349Asn), has been identified in patients with familial pulmonary fibrosis. Asp349 is located in the active site of the C-terminal domain and participates in substrate binding. The Asp349Asn substitution reduces catalytic activity by >90% in vitro. However, the penetrance of this variant is incomplete, suggesting that additional genetic or environmental factors are required for disease manifestation. ### 4.3 Somatic Mutations in Cancer Analysis of somatic mutation data from The Cancer Genome Atlas (TCGA) has revealed recurrent *EPHX2* mutations in several tumor types. The highest mutation frequencies are observed in: - **Colorectal adenocarcinoma:** ~4% of cases harbor somatic *EPHX2* mutations, predominantly missense mutations in the C-terminal domain. - **Lung squamous cell carcinoma:** ~3% of cases exhibit mutations, including a recurrent hotspot at residue Arg333 (R333C), which is part of the catalytic triad. - **Hepatocellular carcinoma:** ~2% of cases show mutations, with a bias toward truncating mutations (nonsense and frameshift). The functional impact of these somatic mutations is context-dependent. Some mutations, such as R333C, are predicted to be loss-of-function and may result in elevated EET levels, which could promote tumor angiogenesis. Conversely, gain-of-function mutations that increase sEH activity would reduce EET levels and potentially suppress anti-tumor immunity. The net effect of *EPHX2* mutations on tumor progression remains an active area of investigation. ### 4.4 Clinical Differentials and Diagnostic Considerations The clinical presentation of altered sEH activity is nonspecific and overlaps with many common conditions. Key differential diagnoses to consider when evaluating a patient with suspected sEH dysfunction include: - **Essential hypertension:** sEH dysfunction should be considered in patients with resistant hypertension, particularly those with a family history of early-onset cardiovascular disease. - **Chronic kidney disease:** Reduced sEH activity may contribute to proteinuria and progressive renal decline. Genetic testing for *EPHX2* variants may be informative in patients with unexplained CKD. - **Pulmonary fibrosis:** Given the association of *EPHX2* variants with familial pulmonary fibrosis, genetic screening may be warranted in patients with a strong family history. - **Neuropathic pain:** sEH inhibitors are being investigated for the treatment of neuropathic pain, and genetic variants that alter sEH activity may influence individual responses to these therapies. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Modulation of EPHX2 Expression The *EPHX2* gene product is not a canonical receptor for viral entry, but its expression is modulated by several viral infections, with functional consequences for viral pathogenesis. **Hepatitis C virus (HCV):** HCV infection of hepatocytes leads to a significant upregulation of *EPHX2* mRNA and protein. This upregulation is mediated by the HCV core protein, which activates the transcription factor Sp1, a known regulator of *EPHX2* promoter activity. The increased sEH activity in HCV-infected livers contributes to the degradation of EETs, promoting hepatic inflammation and fibrosis. Furthermore, elevated sEH activity has been linked to the development of hepatocellular carcinoma in the context of chronic HCV infection. **Influenza A virus:** Infection of airway epithelial cells with influenza A virus results in a transient downregulation of *EPHX2* expression. This downregulation is mediated by the viral NS1 protein, which inhibits the host mRNA splicing machinery, leading to reduced levels of mature *EPHX2* mRNA. The resulting increase in EET levels may contribute to the excessive inflammatory response and acute lung injury associated with severe influenza infection. **SARS-CoV-2:** Transcriptomic analysis of lung tissue from COVID-19 patients has revealed altered expression of *EPHX2* in the context of severe disease. Specifically, *EPHX2* expression is significantly reduced in lung epithelial cells from patients with acute respiratory distress syndrome (ARDS) compared to healthy controls. This downregulation may represent a host protective response to increase EET levels and mitigate the hyperinflammatory state characteristic of severe COVID-19. ### 5.2 Bacterial Pathogen Interactions Bacterial pathogens have also been shown to interact with the EPHX2 gene product. *Mycobacterium tuberculosis* infection of macrophages induces *EPHX2* expression via a Toll-like receptor 2 (TLR2)-dependent mechanism. The increased sEH activity in infected macrophages degrades EETs, which are known to inhibit the growth of intracellular mycobacteria. Thus, *M. tuberculosis* exploits host sEH to create a more permissive intracellular environment. ### 5.3 Immune Evasion Mechanisms The modulation of *EPHX2* expression by pathogens represents a form of immune evasion. By altering the balance between EETs and DHETs, pathogens can suppress the host's anti-inflammatory and antimicrobial responses. For example, the degradation of EETs by sEH reduces the activation of PPARα, which is known to promote the expression of antimicrobial peptides and the resolution of inflammation. This mechanism allows pathogens to establish a more favorable niche for replication and persistence. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Rationale for sEH Inhibition The central role of sEH in degrading cardioprotective and anti-inflammatory EETs has made it an attractive therapeutic target. Pharmacological inhibition of sEH leads to elevated EET levels, which produce vasodilation, reduced blood pressure, decreased inflammation, and enhanced tissue protection in preclinical models of hypertension, atherosclerosis, kidney disease, and stroke. Additionally, the N-terminal phosphatase domain has emerged as a secondary target, with selective inhibitors being developed to modulate LPA signaling. ### 6.2 Urea and Amide-Based sEH Inhibitors The most extensively studied class of sEH inhibitors are urea and amide derivatives that bind to the catalytic site of the C-terminal domain. These compounds act as competitive inhibitors by mimicking the transition state of the epoxide hydrolysis reaction. The urea moiety forms a bidentate hydrogen bond with the catalytic residues Asp333 and His523, creating a stable enzyme-inhibitor complex with picomolar to nanomolar affinity. Key compounds in this class include: - **12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA):** A first-generation sEH inhibitor with an IC50 of approximately 3 nM. AUDA has been extensively used in preclinical studies and demonstrates robust antihypertensive and anti-inflammatory effects in animal models. - **1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU):** A second-generation inhibitor with improved pharmacokinetic properties, including oral bioavailability and a longer half-life. TPPU is currently the most widely used tool compound for studying sEH biology in vivo. - **GSK2256294:** A clinical-stage sEH inhibitor developed by GlaxoSmithKline. GSK2256294 has been evaluated in Phase I and Phase II clinical trials for the treatment of chronic obstructive pulmonary disease (COPD) and diabetic neuropathic pain. ### 6.3 Clinical Trial Status The most advanced clinical program for an sEH inhibitor is GSK2256294. In a Phase IIa trial for COPD, GSK2256294 demonstrated a modest but statistically significant improvement in exercise tolerance and a reduction in systemic inflammatory markers. However, the trial did not meet its primary endpoint of improving lung function, and further development for this indication has been deprioritized. A second clinical program, EC5026 (developed by EicOsis), is being evaluated for the treatment of neuropathic pain. In a Phase I trial, EC5026 was well-tolerated and demonstrated analgesic efficacy in a subset of patients with chronic pain. A Phase II trial is currently underway to assess its efficacy in patients with diabetic peripheral neuropathy. ### 6.4 N-Terminal Phosphatase Inhibitors Selective inhibitors of the N-terminal phosphatase domain have been developed more recently. These compounds are typically based on a phosphate or phosphonate scaffold that mimics the substrate LPA. The most advanced compound, **compound 1770**, exhibits an IC50 of approximately 200 nM against the N-terminal phosphatase domain with >100-fold selectivity over the C-terminal epoxide hydrolase domain. Preclinical studies have shown that compound 1770 reduces LPA-mediated cell migration and invasion in cancer cell lines, suggesting potential utility in oncology. ### 6.5 Pharmacogenomic Considerations Genetic variation in *EPHX2* may influence individual responses to sEH inhibitors. Patients carrying the R287Q loss-of-function variant have lower baseline sEH activity and may require lower doses of sEH inhibitors to achieve therapeutic effects. Conversely, patients with high-activity variants may be less responsive to standard dosing. Prospective pharmacogenomic studies are needed to determine the optimal dosing strategy based on *EPHX2* genotype. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for *EPHX2*: | **Database** | **Accession / Identifier** | **Description** | |---|---|---| | **NCBI Gene** | 2053 | Gene ID for *EPHX2* | | **Ensembl** | ENSG00000120915 | Gene ID for *EPHX2* | | **UniProt** | P34913 | Protein entry for human sEH | | **RCSB PDB** | 1VJ5, 1ZD3, 1ZD4, 3I1Y, 4H0Y | Representative crystal structures | | **OMIM** | 132811 | Mendelian Inheritance in Man entry | | **ClinVar** | Various | Clinical variant interpretations | | **HGNC** | 3402 | Gene nomenclature committee entry | | **STRING** | 9606.ENSP00000335127 | Protein-protein interaction network | | **BioGRID** | 108205 | Interaction database entry | | **Gene Ontology (GO)** | GO:0004301 (epoxide hydrolase); GO:0052725 (LPA phosphatase); GO:0005737 (cytoplasm) | Functional annotations | | **KEGG** | hsa:2053 | KEGG pathway mapping | | **Reactome** | R-HSA-2142691 | Arachidonic acid metabolism pathway | | **GTEx** | ENSG00000120915.12 | Tissue-specific expression data | --- ## Related Clinical & Scientific Guides * [DPP4 (CD26): MERS-CoV Receptor Attachment, Dipeptidyl Peptidase Activity, and Metabolic Tropism](/knowledge/bioinformatics/genes/virology-receptors/dpp4-gene-structure-function-pathway) * [ANPEP (CD13): Aminopeptidase N Structure and Coronavirus Receptor Attachment Mechanisms](/knowledge/bioinformatics/genes/virology-receptors/anpep-gene-structure-function-pathway) * [TMPRSS2 (Transmembrane Protease Serine 2): Spike Cleavage Activation and Host Cell Entry](/knowledge/bioinformatics/genes/virology-receptors/tmprss2-gene-structure-function-pathway) ## References 1. Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: their roles and interactions with lipid metabolism. *Prog Lipid Res*. 2005;44(1):1-51. doi:10.1016/j.plipres.2004.10.001. https://pubmed.ncbi.nlm.nih.gov/15748653/ 2. Morisseau C, Hammock BD. Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. *Annu Rev Pharmacol Toxicol*. 2013;53:37-58. doi:10.1146/annurev-pharmtox-011112-140244. https://pubmed.ncbi.nlm.nih.gov/23020295/ 3. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. *Nat Rev Drug Discov*. 2009;8(10):794-805. doi:10.1038/nrd2875. https://pubmed.ncbi.nlm.nih.gov/19784413/ 4. Gomez GA, Morisseau C, Hammock BD, Christianson DW. Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. *Biochemistry*. 2004;43(16):4716-4723. doi:10.1021/bi036221j. https://pubmed.ncbi.nlm.nih.gov/15096038/ 5. Argiriadi MA, Morisseau C, Hammock BD, Christianson DW. Detoxification of environmental mutagens and carcinogens: structure, mechanism, and evolution of liver epoxide hydrolase. *Proc Natl Acad Sci U S A*. 1999;96(19):10637-10642. doi:10.1073/pnas.96.19.10637. https://pubmed.ncbi.nlm.nih.gov/10485878/ 6. Lee KS, Liu JY, Wagner KM, et al. Optimized inhibitors of soluble epoxide hydrolase improve in vivo target engagement in a mouse model of acute pancreatitis. *J Pharmacol Exp Ther*. 2014;350(2):312-322. doi:10.1124/jpet.114.214346. https://pubmed.ncbi.nlm.nih.gov/24849925/ 7. Zhang G, Panigrahy D, Mahakian LM, et al. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. *Proc Natl Acad Sci U S A*. 2013;110(16):6530-6535. doi:10.1073/pnas.1304321110. https://pubmed.ncbi.nlm.nih.gov/23576738/ 8. Panigrahy D, Kalish BT, Huang S, et al. Epoxyeicosanoids promote organ and tissue regeneration. *Proc Natl Acad Sci U S A*. 2013;110(33):13528-13533. doi:10.1073/pnas.1311565110. https://pubmed.ncbi.nlm.nih.gov/23898209/ 9. Zhang LN, Vincelette J, Cheng Y, et al. Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction and improves vascular function in diabetic mice. *J Cardiovasc Pharmacol*. 2011;58(3):271-278. doi:10.1097/FJC.0b013e3182244e7e. https://pubmed.ncbi.nlm.nih.gov/21629122/ 10. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. *J Biol Chem*. 2000;275(51):40504-40510. doi:10.1074/jbc.M008106200. https://pubmed.ncbi.nlm.nih.gov/11001946/ 11. Enayetallah AE, French RA, Thibodeau MS, Grant DF. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and the effect of fatty acid amide hydrolase inhibitor. *J Comp Neurol*. 2004;478(3):251-262. doi:10.1002/cne.20288. https://pubmed.ncbi.nlm.nih.gov/15368531/ 12. Decker M, Adamska M, Cronin A, et al. EH3 (ABHD9): the first member of a new epoxide hydrolase family with high activity for fatty acid epoxides. *J Lipid Res*. 2012;53(11):2547-2555. doi:10.1194/jlr.M024448. https://pubmed.ncbi.nlm.nih.gov/22956782/ 13. Harris TR, Hammock BD. Soluble epoxide hydrolase: gene structure, expression and deletion. *Gene*. 2013;526(2):61-74. doi:10.1016/j.gene.2013.05.008. https://pubmed.ncbi.nlm.nih.gov/23701967/ 14. Morisseau C, Inceoglu B, Schmelzer K, et al. Naturally occurring monoepoxides of eicosapentaenoic acid and